Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants

Bo-Hao Tang1, Yue-E Wu1, Chen Kou2

  • 1Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.

Insights

This study established evidence-based amoxicillin dosage regimens for neonates and young infants. New dosing recommendations ensure optimal treatment of bacterial infections by considering developmental pharmacokinetics and pharmacodynamics.

Area of Science:

  • Pharmacology
  • Neonatal Medicine
  • Infectious Diseases

Background:

  • Amoxicillin is a key antibiotic for neonatal bacterial infections.
  • Significant variability exists in current amoxicillin dosing regimens for neonates.
  • Limited pharmacokinetic data is available for preterm neonates.

Purpose of the Study:

  • To evaluate population pharmacokinetics of amoxicillin in a large cohort of neonates and young infants.
  • To develop evidence-based amoxicillin dosage regimens using developmental pharmacokinetics-pharmacodynamics.
  • To optimize antibiotic therapy for neonatal bacterial infections.

Main Methods:

  • Prospective, multicenter pharmacokinetic study with opportunistic sampling.
  • Amoxicillin plasma concentrations measured by high-performance liquid chromatography.
  • Population pharmacokinetic analysis using NONMEM, with covariate analysis and model validation.

Main Results:

  • A two-compartment model identified current weight, postnatal age, and gestational age as significant covariates.
  • Simulations showed current regimens achieve pharmacodynamic targets in 79.0%-99.0% of neonates, depending on sepsis type and prematurity.
  • Established new dosage regimens based on developmental pharmacokinetics-pharmacodynamics.

Conclusions:

  • Population pharmacokinetics of amoxicillin in neonates and young infants were characterized.
  • Evidence-based amoxicillin dosage regimens were established for improved neonatal infection treatment.
  • Optimized dosing can enhance therapeutic outcomes and minimize resistance.

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
295
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
750
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
677
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
247
Conservation of Small Populations02:04

Conservation of Small Populations

Small population sizes put a species at extreme risk of extinction due to a lack of variation, and a consequent decrease in adaptability. This weakens the chances of survival under pressures such as climate change, competition from other species, or new diseases. Large populations are more likely to survive pressures such as these, as such populations are more likely to harbor individuals that have genetic variants that are adaptive under new stresses. Small populations are much less...
17.3K